marketshareAI
Theme

Oxf Nanopore Technologies

ONTHealthcare
124.70GBX
-4.30%
Market Cap
1.20B
Volume
1.18M
66% of avg
P/E Ratio
-8.64
EPS (TTM)
-14.43
Beta
0.82
Day Range
124.70p - 132.50p
52 Week Range
88.60p124.70p224.80p
124.70p

Upcoming Events

1 January 2026
Mandatory lead audit partner rotation
End of 2026
CEO Gordon Sanghera to step down
High Impact Event
31 December 2026
CEO Gordon Sanghera to step down
FY 2027
Target to reach adjusted EBITDA breakeven
High Impact Event
FY 2028
Target to become cash flow positive
High Impact Event
ONT
NEUTRAL

Oxford Nanopore to Participate in Upcoming Investor Conferences

The healthcare technology company will be presenting at several investor conferences in December.

ONT
NEUTRAL

Oxford Nanopore Director Increases Shareholding

The Chief Financial Officer of the biotechnology company has purchased additional shares through the company's Share Incentive Plan.

ONT
NEUTRAL

Oxford Nanopore postpones investor event, reaffirms guidance

The biotechnology company is postponing a virtual investor event as it undergoes a CEO transition, but reaffirms its full-year 2025 revenue growth guidance.

ONT
NEUTRAL

Oxford Nanopore to Host Investor Event and Participate in Upcoming Conferences

The biotechnology company will be hosting an investor event and participating in several investor conferences in November.

ONT
NEUTRAL

Oxford Nanopore Director Increases Shareholding

The chief financial officer of the biotechnology company has purchased additional shares through the company's share incentive plan.

ONT
NEUTRAL

Oxford Nanopore Director Increases Shareholding

The chief financial officer of the biotechnology company has purchased additional shares through the company's share incentive plan.

ONT
GOOD

Oxford Nanopore Reports Strong H1 Growth, Reaffirms Full Year Guidance

This molecular sensing technology company reported strong H1 revenue growth of 28% at constant currency, with broad-based expansion across all regions and customer segments. Despite ongoing losses, adjusted EBITDA improved significantly.

ONT
NEUTRAL

Oxford Nanopore Director Purchases Shares Under SIP

The Chief Financial Officer of the biotechnology company has purchased shares under the firm's employee share plan.

ONT
NEUTRAL

Oxford Nanopore Announces CEO Succession Plan

The biotechnology company has announced that its long-serving CEO will step down by the end of 2026, triggering a formal search for a successor.

ONT
NEUTRAL

Oxford Nanopore Reappoints Deloitte as Auditor

The biotechnology company has reappointed Deloitte as its external auditor, following a formal tender process.